Neumentum

Executive Summary

Neumentum is a clinical-stage biopharmaceutical company dedicated to developing non-opioid treatments for acute and chronic pain, addressing the critical unmet need for safer alternatives to opioids. Founded in 2016 and based in Morristown, New Jersey, the company’s pipeline includes four novel small-molecule product candidates targeting pain and neurology indications. Its lead candidate, NTM-001, is a non-opioid analgesic designed to avoid abuse potential and serious side effects, with a focus on acute pain management. Neumentum aims to capitalize on the growing regulatory and societal push to reduce opioid prescribing, positioning itself as a potential leader in the non-opioid pain market. As a private company, it has not disclosed recent funding rounds or valuation, but its clinical progress and focus on a high-demand therapeutic area suggest significant upside potential. However, the lack of disclosed pipeline details and early-stage nature imply high execution risk.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for NTU-001 in acute pain50% success
• Q2 2027Initiation of Phase 3 trial for NTU-002 in chronic pain70% success
• Q1 2027New partnership or licensing deal for non-opioid pipeline40% success